Targeted next‐generation sequencing and non‐coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes
暂无分享,去创建一个
Gorka Larrinaga | O. Hes | J. López | C. Lawrie | M. Fernández-Mercado | L. Manterola | Erika Larrea | I. Goicoechea | M. Arestin | Ondrej Hes | Charles H Lawrie | Erika Larrea | Ibai Goicoechea | Marı́a Arestin | Marta Fernandez-Mercado | Francisco Cáceres | Lorea Manterola | José I López | G. Larrinaga | F. Cáceres | M. Arestín
[1] M. V. van Dijk,et al. The entire miR‐200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney , 2013, Genes, chromosomes & cancer.
[2] Xiaokun Zhao,et al. microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells , 2012, Molecular medicine reports.
[3] R. Dahiya,et al. MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. , 2012, Carcinogenesis.
[4] Huiqing Liu,et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma , 2010, BMC Systems Biology.
[5] Yuri E Nikiforov,et al. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. , 2013, Chest.
[6] R. Shah,et al. Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components: The Utility of Immunohistochemical and Cytogenetical Analyses in Differential Diagnosis , 2008, The American journal of surgical pathology.
[7] A. Gerger,et al. MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. , 2012, Anticancer research.
[8] M. Seto,et al. Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c , 2008, The Journal of pathology.
[9] Y Dai,et al. Microarray analysis of microRNA expression in renal clear cell carcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[10] George M Yousef,et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. , 2010, Clinical biochemistry.
[11] C. Pan,et al. Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study. , 2011, Annals of diagnostic pathology.
[12] Andrea J. O'Hara,et al. Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. , 2008, Blood.
[13] D. Grignon,et al. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile , 2013, Modern Pathology.
[14] P. Schirmacher,et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. , 2000, Cancer research.
[15] J. Ragoussis,et al. The role of hypoxia regulated microRNAs in cancer. , 2010, Current topics in microbiology and immunology.
[16] D. Grignon,et al. Clear Cell Papillary Renal Cell Carcinoma–like Tumors in Patients With Von Hippel-Lindau Disease Are Unrelated to Sporadic Clear Cell Papillary Renal Cell Carcinoma , 2013, The American journal of surgical pathology.
[17] B. Delahunt,et al. Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney , 2010, The American journal of surgical pathology.
[18] M. Korpal,et al. The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.
[19] Hanlin Gao,et al. MicroRNA profiling of clear cell renal cell carcinoma by whole‐genome small RNA deep sequencing of paired frozen and formalin‐fixed, paraffin‐embedded tissue specimens , 2010, The Journal of pathology.
[20] A. Belldegrun,et al. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. , 2011, The Journal of urology.
[21] Antonio Lopez-Beltran,et al. 2004 WHO classification of the renal tumors of the adults. , 2006, European urology.
[22] V. Reuter,et al. Differential Diagnosis of Renal Tumors With Papillary Architecture , 2011, Advances in anatomic pathology.
[23] Francisco E. Baralle,et al. Genomic variants in exons and introns: identifying the splicing spoilers , 2004, Nature Reviews Genetics.
[24] L. Truong,et al. Immunohistochemical diagnosis of renal neoplasms. , 2011, Archives of pathology & laboratory medicine.
[25] P. Brousset,et al. Specific small nucleolar RNA expression profiles in acute leukemia , 2012, Leukemia.
[26] Marek Svoboda,et al. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy , 2010, Journal of experimental & clinical cancer research : CR.
[27] R. Figlin,et al. Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis , 2012, PloS one.
[28] K. Wagner,et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Mingxia Xiong,et al. The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. , 2012, American journal of physiology. Renal physiology.
[30] M. Sibony,et al. Clear‐cell papillary renal cell carcinoma: 24 cases of a distinct low‐grade renal tumour and a comparative genomic hybridization array study of seven cases , 2011, Histopathology.
[31] C. Kimchi-Sarfaty,et al. Understanding the contribution of synonymous mutations to human disease , 2011, Nature Reviews Genetics.
[32] W. Dinjens,et al. Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencing , 2013, Virchows Archiv.
[33] Jun Li,et al. Biomarkers , Genomics , Proteomics , and Gene Regulation miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival , 2010 .
[34] P. Argani,et al. Renal cell carcinoma with clear cell and papillary features. , 2012, Archives of pathology & laboratory medicine.
[35] D. Polsky,et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor , 2009, Proceedings of the National Academy of Sciences.
[36] H. Aburatani,et al. Papillary Renal Cell Carcinoma: Quantitation of Chromosomes 7 and 17 by FISH, Analysis of Chromosome 3p for LOH, and DNA Ploidy , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[37] R. Salgia,et al. The role of the c-Met pathway in lung cancer and the potential for targeted therapy , 2011, Therapeutic advances in medical oncology.
[38] Holger Moch,et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.
[39] F. Marincola,et al. Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population , 2012, Medical Oncology.
[40] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[41] Bin Tean Teh,et al. MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.
[42] M. Korpal,et al. The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.
[43] J. Christensen,et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. , 2009, Cancer research.
[44] B. Druker,et al. MET receptor sequence variants R970C and T992I lack transforming capacity. , 2010, Cancer research.
[45] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[46] R. Albert,et al. miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma , 2012, Oncogenesis.
[47] K. Hoang-Xuan,et al. Prognostic impact of the isocitrate dehydrogenase 1 single‐nucleotide polymorphism rs11554137 in malignant gliomas , 2013, Cancer.
[48] Jörg Grigull,et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. , 2011, The Journal of urology.
[49] J. López. Renal tumors with clear cells. A review. , 2013, Pathology, research and practice.
[50] I. Thompson,et al. Elevated snoRNA biogenesis is essential in breast cancer , 2014, Oncogene.
[51] M. Seto,et al. Overexpression of miR‐210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells , 2011, The Journal of pathology.
[52] D. L. Souza,et al. [Incidence, prevalence and mortality of kidney cancer in Spain: estimates and projections for the 1998-2022 period]. , 2012, Actas urologicas espanolas.
[53] D. McCance. Pathological Society of Great Britain and Ireland , 1984 .
[54] M. Michael,et al. The VHL-dependent regulation of microRNAs in renal cancer , 2010, BMC medicine.
[55] Ling Wang,et al. Pre-Micro RNA Signatures Delineate Stages of Endothelial Cell Transformation in Kaposi Sarcoma , 2009, PLoS pathogens.
[56] F. Farzaneh,et al. Are snoRNAs and snoRNA host genes new players in cancer? , 2012, Nature Reviews Cancer.
[57] M. Rosenblum,et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel–Lindau gene and hypoxia-inducible factor pathway-related proteins , 2011, Modern Pathology.
[58] Y. Nagashima,et al. Pathological and molecular biological aspects of the renal epithelial neoplasms, up‐to‐date , 2004, Pathology international.
[59] George A Calin,et al. Micro-RNA profiling in kidney and bladder cancers. , 2007, Urologic oncology.
[60] K. Mai,et al. Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study , 2009, Virchows Archiv.
[61] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[62] S. Spivack,et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.
[63] George M Yousef,et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. , 2010, The Journal of urology.
[64] Hongbing Shen,et al. A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population , 2012, Journal of biomedical research.
[65] P. Grossmann,et al. Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney , 2011, Virchows Archiv.
[66] W. Linehan,et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.
[67] G. Bhanot,et al. Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.
[68] M. Naujokas,et al. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. , 2002, Molecular biology of the cell.
[69] T. Matsuyama,et al. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation , 2001, Oncogene.
[70] Sun-Mi Park,et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.
[71] S. Fröhling,et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. , 2007, Blood.
[72] L. Strong,et al. Activating mutation in MET oncogene in familial colorectal cancer , 2011, BMC Cancer.
[73] J. Larkin,et al. Epigenetic regulation in RCC: opportunities for therapeutic intervention? , 2012, Nature Reviews Urology.
[74] P. Tassone,et al. The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma , 2012, Blood Cancer Journal.
[75] R. Lothe,et al. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. , 2012, Neoplasia.
[76] L. Schmidt,et al. A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.
[77] R. Shah,et al. Clear Cell Papillary Renal Cell Carcinoma: A Distinct Histopathologic and Molecular Genetic Entity , 2008, The American journal of surgical pathology.
[78] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[79] L. Truong,et al. Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? , 2012, Archives of pathology & laboratory medicine.
[80] Jeong Hwan Park,et al. Clear Cell Papillary Renal Cell Carcinoma: A Report of 15 Cases Including Three Cases of Concurrent Other-Type Renal Cell Carcinomas , 2012, Korean journal of pathology.
[81] M. Esteller,et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis , 2011, Oncogene.
[82] T. Enver,et al. MicroRNA expression in lymphocyte development and malignancy , 2008, Leukemia.
[83] P. Hirvikoski,et al. Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma , 2010, Journal of experimental & clinical cancer research : CR.